Please check your internet connection and try again.
# Piperacillin-Tazobactam
## Overview
Piperacillin-tazobactam is a combination penicillin-class antibiotic and beta-lactamase inhibitor used to treat a variety of bacterial infections. Piperacillin is a broad-spectrum bactericidal antibiotic, while tazobactam protects piperacillin from degradation by beta-lactamase enzymes produced by susceptible bacteria.
## Primary Indications
* Complicated intra-abdominal infections
* Complicated skin and skin structure infections
* Community-acquired pneumonia
* Hospital-acquired pneumonia (including ventilator-associated pneumonia)
* Empirical treatment of febrile neutropenia
## Adult Dosing
* **Standard Dose:** 3.375 grams (3g piperacillin/0.375g tazobactam) IV every 6 hours or 4.5 grams (4g piperacillin/0.5g tazobactam) IV every 8 hours.
* **Severe/Life-Threatening Infections or Nosocomial Infections:** 4.5 grams (4g piperacillin/0.5g tazobactam) IV every 6 hours.
* **Duration:** Typically 7-14 days, depending on the indication and clinical response.
## Pediatric Dosing
Dosing for pediatric patients is based on the piperacillin component and should be calculated by weight. Renal and hepatic function should be considered.
* **Neonates and Infants (0-2 months):** Dosing varies significantly by gestational age and postnatal age. Consult specific guidelines.
* **Children (2 months and older) weighing up to 40 kg:** 100 mg piperacillin/12.5 mg tazobactam per kg per dose IV every 6 hours.
* **Children (2 months and older) weighing > 40 kg:** Use adult dosing.
* **Maximum Doses:** Not to exceed the maximum adult dose.
## Dose Adjustments
* **Renal Impairment (CrCl < 20 mL/min):** Reduce dose frequency. For the 3.375g dose given every 6 hours, administer every 8 hours. For the 4.5g dose given every 8 hours, administer every 12 hours. If CrCl is 20-40 mL/min, consider extending the dosing interval.
* **Hepatic Impairment:** No specific dose adjustment is typically recommended, but caution is advised due to potential for accumulation.
## Contraindications
* Known severe hypersensitivity to piperacillin, tazobactam, other penicillin derivatives, or beta-lactamase inhibitors.
## Adverse Effects
* **Common:** Diarrhea, nausea, vomiting, rash, headache, insomnia, elevated liver enzymes (ALT, AST).
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), seizures (rare, especially with high doses or renal impairment), neutropenia, thrombocytopenia, interstitial nephritis.
## Key Drug Interactions
* **Probenecid:** May increase and prolong piperacillin-tazobactam serum concentrations.
* **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the neuromuscular blockade.
* **Warfarin:** May decrease the effect of warfarin; increased INR monitoring is recommended.
* **Methotrexate:** Piperacillin may decrease methotrexate clearance; monitor methotrexate levels.
## Monitoring
* Renal function (baseline and during therapy, especially with impaired renal function or concomitant nephrotoxic agents).
* Liver function tests.
* Complete blood count (particularly for prolonged therapy or in patients with neutropenia).
* Signs and symptoms of infection.
* Monitor for signs of hypersensitivity reactions.
* Monitor for diarrhea and rule out *C. difficile*-associated diarrhea.
## Clinical Pearls
* Piperacillin-tazobactam is generally administered by IV infusion over 30 minutes. Rapid infusion can increase the risk of seizures.
* The dose is expressed as piperacillin/tazobactam. For example, 3.375g contains 3g of piperacillin and 0.375g of tazobactam.
* This combination is active against many Gram-positive, Gram-negative, and anaerobic bacteria, including *Pseudomonas aeruginosa*.
* Ensure adequate hydration to minimize the risk of crystalluria.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and institutional guidelines for complete details. Dosing may vary based on patient-specific factors, institutional protocols, and the severity and location of infection.*
